XBiotech
XBIT
45 hedge funds and large institutions have $11.1M invested in XBiotech in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 17 reducing their positions, and 16 closing their positions.
0.99% less ownership
Funds ownership: 11.04% → 10.05% (-0.99%)
20% less funds holding
Funds holding: 56 → 45 (-11)
29% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 17
41% less capital invested
Capital invested by funds: $18.9M → $11.1M (-$7.84M)
69% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$482K |
| 2 |
Renaissance Technologies
New York
|
+$362K |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$177K |
| 4 |
Two Sigma Advisers
New York
|
+$177K |
| 5 |
RC
RBF Capital
San Francisco,
California
|
+$109K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$691K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$455K |
| 3 |
Morgan Stanley
New York
|
-$417K |
| 4 |
E
Ergoteles
New York
|
-$395K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$380K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Squarepoint
New York
| – | -$63K | -11,189 | Closed |
|
52
Goldman Sachs
New York
| – | -$57K | -10,102 | Closed |
|
53
Group One Trading
Chicago,
Illinois
| – | -$23K | -4,000 | Closed |
|
54
Legal & General Group
London,
United Kingdom
| – | -$7K | -1,257 | Closed |
|
55
Citigroup
New York
| – | -$1K | -151 | Closed |
|
56
Simplex Trading
Chicago,
Illinois
| – | -$687 | -146 | Closed |
|
57
New York State Common Retirement Fund
Albany,
New York
| – | -$1K | -140 | Closed |
|
58
Wells Fargo
San Francisco,
California
| – | +$71 | +15 | +15% |
|
XBIT Hedge Fund Activity: Q3 2022 in Review
45 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in XBiotech (XBIT) for Q3 2022, worth a combined $11.1M — down 41% from $18.9M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of XBIT and 5 opened new positions — a net loss of 11 holders — while 17 trimmed existing stakes and 12 added.
The largest buyer was Bridgeway Capital Management, adding an estimated $482K. The largest seller was Millennium Management, cutting an estimated $691K.
- 45 institutional investors held XBiotech (XBIT) as of Q3 2022, down from 56 in Q2 2022.
- Funds reported $11.1M of XBiotech stock for Q3 2022, down 41% quarter-over-quarter.
- 5 funds opened new XBiotech positions in Q3 2022 and 16 closed out, a net change of -11 holders.
- The largest XBiotech buyer in Q3 2022 was Bridgeway Capital Management, an estimated $482K added.
- The largest XBiotech seller in Q3 2022 was Millennium Management, an estimated $691K sold.
Based on aggregated 13F filings for Q3 2022.